TCM
OTLK icon

Tradewinds Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Tradewinds Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$106 – 723
2025
Q3 		$106 Buy
+100
New +$173 ﹤0.01% 649

Other funds holding OTLK

SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tradewinds Capital Management's OTLK Position: Q4 2025 in Review

Tradewinds Capital Management sold out of Outlook Therapeutics (OTLK) in Q4 2025, closing a stake of 100 shares — an estimated $106 sold.

Tradewinds Capital Management first reported a position in OTLK in Q3 2025 and held it in 1 quarter. The position peaked at $106 in Q3 2025. 53 funds tracked by Wall St. Rank hold OTLK as of Q4 2025.

  • Tradewinds Capital Management reported no remaining Outlook Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tradewinds Capital Management sold 100 Outlook Therapeutics shares in Q4 2025, an estimated $106.
  • Tradewinds Capital Management first reported a position in Outlook Therapeutics in Q3 2025 and held it in 1 quarter.
  • Tradewinds Capital Management's Outlook Therapeutics position peaked at $106 in Q3 2025.
  • 53 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2025.

Based on Tradewinds Capital Management's 13F filing for Q4 2025, filed 14 Jan 2026.